ClinicalTrials.gg
CompletedNCT03646604Updated Feb 10, 2025

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

A Phase 1 interventional study of Upadacitinib (ABT-494) in Atopic Dermatitis, sponsored by AbbVie. Completed at 18 sites in 3 countries. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
2 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
14th of 17
35 · median 272
Started
2019
with 1 other
Phase 1
Only one
of the 17
Registered
5th of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 14th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 1, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 2 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric participants with severe atopic dermatitis and to evaluate palatability of upadacitinib oral solution in pediatric participants.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Upadacitinib
  • ABT-494
  • Atopic Dermatitis
  • RINVOQ
04

Who can participate

Ages eligible
2 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with total body weight of 10 kilograms(kg) or higher at Baseline. Beginning with protocol version 6.0, only subjects 3 years of age and older will be enrolled for the remainder of this study.
  • Diagnosed with atopic dermatitis (AD) with onset of symptoms at least 6 months prior to baseline.
  • Meets Hanifin and Rajka criteria for AD.
  • Diagnosed with active severe AD defined by Eczema Area Severity Index (EASI), Validated Investigator's Global Assessment (IGA) and body surface area (BSA).
  • Documented history (within 12 months prior to the Baseline Visit) of inadequate response or intolerance to topical (TCS) and topical calcineurin inhibitor (TCI) OR for whom use of TCS and TCIs is otherwise medically inadvisable.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to Janus Kinase (JAK) inhibitor.
  • Requirement of prohibited medications during the study.
  • Current use of known moderate or strong inhibitors or inducers of drug metabolizing enzymes within 30 days prior to the first dose of study drug and through the end of Part 1 of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Part 1; Cohort 1

    Participants, 6 to \<12 years of age, will receive low dose of upadacitinib.

    Drug: Upadacitinib (ABT-494)

  • Experimental
    Part 1; Cohort 2

    Participants, 6 to \<12 years of age, will receive high dose of upadacitinib.

    Drug: Upadacitinib (ABT-494)

  • Experimental
    Part 1; Cohort 3

    Participants, 2 to \<6 years of age, will receive low dose of upadacitinib.

    Drug: Upadacitinib (ABT-494)

  • Experimental
    Part 1; Cohort 4

    Participants, 2 to \<6 years of age, will receive high dose of upadacitinib.

    Drug: Upadacitinib (ABT-494)

  • Experimental
    Part 2

    Eligible participants who completed Part 1 will receive weight-dependant low dose of upadacitinib.

    Drug: Upadacitinib (ABT-494)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    It is defined as the maximum observed plasma concentration (Cmax) for upadacitinib.

    Time frame: Up to 7 days

  2. Time to Maximum Observed Plasma Concentration (Tmax)

    It is defined as the time to maximum plasma concentration (Tmax) of upadacitinib.

    Time frame: Up to 7 days

  3. Area under the plasma concentration-time curve within a dosing interval (AUCtau)

    The area under the plasma concentration-time curve (AUCtau) is a method of measurement of the total exposure of a drug in plasma.

    Time frame: Up to 7 days

  4. Oral Clearance

    Clearance is defined the volume of plasma cleared of the drug per unit time.

    Time frame: Up to 7 days

  5. Number of Participants With Treatment Emergent Adverse Events (TEAE)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.

    Time frame: Up to 2 years

07

Study locations

18 sites
  • Beach Pediatrics /ID# 207834
    Huntington Beach, California 92647-6818, United States
  • Children's Hospital Los Angeles /ID# 206042
    Los Angeles, California 90027, United States
  • Pediatric Skin Research, LLC /ID# 213468
    Coral Gables, Florida 33146-1837, United States
  • Rybear, Inc /ID# 231801
    Fort Lauderdale, Florida 33316-1952, United States
  • IACT Health-Columbus /ID# 216370
    Columbus, Georgia 31904-8946, United States
  • Northwestern University Feinberg School of Medicine /ID# 206224
    Chicago, Illinois 60611-2927, United States
  • Dawes Fretzin, LLC /ID# 214958
    Indianapolis, Indiana 46256, United States
  • Duplicate_Washington University of St. Louis /ID# 206972
    Saint Louis, Missouri 63141-6399, United States
  • University of New Mexico School of Medicine /ID# 206757
    Albuquerque, New Mexico 87131-0001, United States
  • Cincinnati Children's Hospital /ID# 207071
    Cincinnati, Ohio 45229, United States
  • Oregon Medical Research Center /ID# 206226
    Portland, Oregon 97239, United States
  • Penn State University and Milton S. Hershey Medical Center /ID# 207096
    Hershey, Pennsylvania 17033-2360, United States
  • Paddington Testing Co., Inc. /ID# 207079
    Philadelphia, Pennsylvania 19103, United States
  • Arlington Research Center, Inc /ID# 222901
    Arlington, Texas 76011, United States
  • West Virginia University Hospitals /ID# 206792
    Morgantown, West Virginia 26506, United States
  • Haukeland University Hospital /ID# 210162
    Bergen, Hordaland 5021, Norway
  • Rikshospitalet OUS HF /ID# 210163
    Oslo, 0450, Norway
  • Alma M. Cruz Santana, MD-Private practice /ID# 214890
    Carolina, 00985, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Aug 2024, 66 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 66 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2018
First posted
Aug 24, 2018
StartActual
Jan 31, 2019
Primary completionActual
Aug 29, 2024
CompletionActual
Aug 29, 2024
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03646604
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 24, 2018
Start date
Jan 31, 2019
Primary completion
Aug 29, 2024
Completion
Aug 29, 2024
Last update
Feb 10, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion